Carole Huntsman Sells 910 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) insider Carole Huntsman sold 910 shares of the stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $493.78, for a total value of $449,339.80. Following the transaction, the insider directly owned 9,122 shares of the company’s stock, valued at $4,504,261.16. This trade represents a 9.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Carole Huntsman also recently made the following trade(s):

• On Friday, November 21st, Carole Huntsman sold 1,958 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $553.11, for a total value of $1,082,989.38.

Madrigal Pharmaceuticals Stock Up 3.9%

MDGL traded up $18.72 during trading on Monday, reaching $499.17. 336,495 shares of the stock were exchanged, compared to its average volume of 364,506. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.26 and a current ratio of 3.44. The stock’s 50 day moving average price is $559.15 and its two-hundred day moving average price is $460.34. Madrigal Pharmaceuticals, Inc. has a twelve month low of $265.00 and a twelve month high of $615.00. The stock has a market cap of $11.34 billion, a P/E ratio of -38.37, a price-to-earnings-growth ratio of 4.66 and a beta of -1.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 41.50% and a negative net margin of 39.04%. Equities analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP lifted its position in shares of Madrigal Pharmaceuticals by 8.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 2,141,701 shares of the biopharmaceutical company’s stock valued at $982,313,000 after acquiring an additional 165,683 shares during the period. William Blair Investment Management LLC increased its position in shares of Madrigal Pharmaceuticals by 17.6% in the third quarter. William Blair Investment Management LLC now owns 411,802 shares of the biopharmaceutical company’s stock worth $188,877,000 after purchasing an additional 61,513 shares during the period. Wellington Management Group LLP raised its stake in Madrigal Pharmaceuticals by 5,381.2% in the third quarter. Wellington Management Group LLP now owns 404,455 shares of the biopharmaceutical company’s stock valued at $185,507,000 after purchasing an additional 397,076 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Madrigal Pharmaceuticals by 96.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 376,163 shares of the biopharmaceutical company’s stock worth $113,842,000 after purchasing an additional 184,554 shares during the period. Finally, Invesco Ltd. grew its stake in Madrigal Pharmaceuticals by 49.5% during the third quarter. Invesco Ltd. now owns 299,565 shares of the biopharmaceutical company’s stock worth $137,398,000 after buying an additional 99,209 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. The Goldman Sachs Group reiterated a “buy” rating and issued a $571.00 price objective on shares of Madrigal Pharmaceuticals in a report on Wednesday, January 14th. Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Citigroup restated an “outperform” rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, January 20th. TD Cowen restated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Monday, January 12th. Finally, HC Wainwright upped their target price on Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the company a “buy” rating in a research report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $632.64.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.